Anticholinergic Drugs Not Harmful to Parkinson’s Patients
There was no difference in cognition between Parkinson’s patients taking a high and lower level of anticholinergic medications.
There was no difference in cognition between Parkinson’s patients taking a high and lower level of anticholinergic medications.
Children with ADHD had weaker connections between three brain networks than children without the condition.
Dr. Robert L. Spitzer contributed immensely to various editions of the DSM and helped get homosexuality removed as a mental disorder.
In a neurocognitive mouse model, rolipram was able to restore a process in the brain that helps to lower toxic protein levels.
NSI-189 has demonstrated the ability to produce new brain cells and has been effective in early stage trials.
Research and resources geared toward non-veterans is not sufficient enough to help them.
In a mouse model of Parkinson’s, LBT-3727 was able to protect dopamine-producing cells.
There was a significant difference in six proteins in those with bipolar I depression compared to the control group.
The FDA’s Psychopharmacologic Drugs Advisory Committee voted 9-4 that gepirone did not demonstrate substantial effectiveness.
The global market for anxiety treatments and antidepressants will decline at a compound annual growth rate of 1.25% between 2014 and 2020.